SCHEMBL6349809

SCHEMBL6349809

ON=C(CCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1

nearest known ligand 0.87

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 18/20 0.87
TMEM97 Q5BJF2 3/20 0.80
SIGMAR1 Q99720 3/20 0.80
DRD2 P14416 8/20 0.77
LMNA P02545 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
HTR1A P08908 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
HTR2A P28223 1/20 0.65
HTR2C P28335 1/20 0.65
CYP2C19 P33261 1/20 0.65
HTR7 P34969 1/20 0.65
DRD3 P35462 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6349808 1.00 DRD4 (0.87) DRD4TMEM97SIGMAR1DRD2LMNA
SCHEMBL6358178 0.93 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2LMNA
SCHEMBL6354317 0.93 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2LMNA
SCHEMBL6354321 0.93 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2LMNA
SCHEMBL6351630 0.90 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2HTR1A
SCHEMBL6352025 0.90 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2HTR1A
SCHEMBL6351628 0.90 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2HTR1A
SCHEMBL6358863 0.88 DRD4 (0.82) DRD4TMEM97SIGMAR1DRD2
SCHEMBL6358866 0.88 DRD4 (0.82) DRD4TMEM97SIGMAR1DRD2
SCHEMBL6357057 0.88 DRD4 (1.00) DRD4TMEM97SIGMAR1DRD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US claimed
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction ABBOTT LABORATORIES 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176727-A1 Oximes and hydrazones that are useful in treating sexual dysfunction CYP19A1, SHBG, CYP17A1 DRD4 1272/4885TMEM97 3004/4885SIGMAR1 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.